340B Drug Pricing Program
Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.
The AHA will continue to fight to protect the 340B program and the patients it benefits against unfounded attacks by big drug companies.
AHA slams group’s proposal that would hurt 340B Program
The AHA today responded to a new group that includes the Pharmaceutical Research and Manufacturers of America, National Association of Community Health Centers and other organizations calling for legislative changes that would hurt the 340B…
Costly innovative cancer treatments and technologies, organizational alignments and shifting sites of care are changing the way care is delivered.
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for funds unlawfully withheld for five years, AHA today asked to meet with the responsible HHS team to discuss its forthcoming remedial proposal.
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for funds unlawfully withheld for five years,
AHA requests the opportunity to meet with HHS now that the district court in American Hospital Association v. Becerra has remanded the question of how to repay 340B hospitals to the Department of Health and Human Services.
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled today in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending…
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending in the…
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled in Sanofi-Aventis U.S. v. HHS et al.